

# ForPatients

by Roche

Alzheimer's Disease (AD)

## A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

**Trial Status**  
Terminated

**Trial Runs In**  
27 Countries

**Trial Identifier**  
NCT03114657 2016-003288-20  
BN29553

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (Q4W) for 100 weeks. The primary efficacy assessment will be performed at 105 weeks. The participants who do not enter open-label extension will enter for a long term follow-up period for up to 52 weeks after the last crenezumab dose (Week 153).

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT03114657 2016-003288-20 BN29553**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>= 50 Years & <= 85 Years

**Healthy Volunteers**  
No

---